All treatments
Treatment
PEGINTERFERON ALFA-2A clinical trials
2 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, multicenter, open-label, randomized study to evaluate the efficacy and safety of fedratinib compared to best available therapy in subjects with DIPSS - intermediate or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis and previously treated with ruxolitinib
This study is comparing a new medicine, fedratinib, with other common treatments for people with a type of bone marrow disorder called myelofibrosis. It's for patients whose myelofibrosis has been treated before with another drug called ruxolitinib. We want to see how well fedratinib shrinks the spleen.
For: Primary myelofibrosis · post-polycythemia vera myelofibrosis · or post-essential thrombocythemia myelofibrosisBelgium · Italy · Hungary - AuthorisedTherapeutic exploratory (Phase II)
Combination Therapy with Interferon-Alpha2a and Ruxolitinib in Newly Diagnosed Patients with Polycythemia Vera. A Danish Safety and Efficacy Study.
This study is looking at two medicines, Peginterferon alfa-2a and Ruxolitinib (Jakavi), together for people newly diagnosed with a blood condition called Polycythemia Vera. Researchers want to see how safe this combination is and how well it works.
For: PolycythemiaDenmark